Protalix BioTherapeutics Reports First Quarter 2026 Financial Results and Reaffirms Guidance

Protalix BioTherapeutics, Inc.

Received $25 million milestone from Chiesi following European Commission approval of Elfabrio 2 mg/kg every-4-weeks dosing regimen.
PRX-115 Phase 2 RELEASE study for uncontrolled gout continues; top-line results expected second half of 2027.
Reaffirms 2026 revenue guidance of $78.0-$83.0 million including $25 million milestone; Elfabrio sales $33-$35 million, Elelyso $20-$23 million.
Cash and equivalents $51 million as of March 31, 2026; no outstanding debt or warrants.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Protalix BioTherapeutics, Inc. updated its the first quarter ended March 31, 2026 guidance (reaffirmed).

Period: the first quarter ended March 31, 2026
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Protalix BioTherapeutics, Inc. (the "Company") issued a press release announcing its financial results for the fiscal quarter ended March 31, 2026

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Protalix BioTherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-059749

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.